Rescue of mutated cardiac ion channels in inherited arrhythmia syndromes

Journal of Cardiovascular Pharmacology

Volumn 56, Issue 2, 2010, Pages 113-122

  Balijepalli, Sadguna Y ^a   Anderson, Corey L ^a   Lin, Eric C ^a   January, Craig T ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; ANTIARRHYTHMIC AGENT; ASTEMIZOLE; CISAPRIDE; FEXOFENADINE; GENTAMICIN; GLYCEROL; ION CHANNEL; MALLOTOXIN; MESSENGER RNA; NORASTEMIZOLE; NS 1643; NS 3623; PD 118057; PD 307243; POTASSIUM CHANNEL HERG; QUATERNARY AMMONIUM DERIVATIVE; QUINIDINE; RPR 260243; THAPSIGARGIN; UNCLASSIFIED DRUG; VRT 325;

CARDIOVASCULAR RISK; CONFERENCE PAPER; DRUG BINDING; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART MUSCLE POTENTIAL; HUMAN; LONG QT SYNDROME; MUTATIONAL ANALYSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN STRUCTURE;

ANIMALS; ARRHYTHMIAS, CARDIAC; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; ION CHANNELS; LONG QT SYNDROME; MUTATION; PROTEIN TRANSPORT;

EID: 77955983683     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181dab014     Document Type: Conference Paper

References (92)

1. Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J. 1957;54:59-68.
2. Romano C, Gemme G, Pongiglione R. [Rare cardiac arrhythmias of the pediatric age. Syncopal attacks due to paroxysmal ventricular fibrillation.]. Clin Pediatr (Bologna). 1963;45:656-683.
3. Ward OC. A new familial cardiac syndrome in children. J Ir Med Assoc. 1964;54:103-106.
4. Selzer A, Wray HW. Quinidine syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation. 1964;30:17-26.
5. Noda M, Ikeda T, Suzuki H, et al. Expression of functional sodium channels from cloned cDNA. Nature. 1986;322:826-828.
6. Warmke JW, Ganetzky B. A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci USA. 1994;91: 3438-3442.
7. Curran ME, Splawski I, Timothy KW, et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995;80: 795-803.
8. Tan BH, Valdivia CR, Rok BA, et al. Common human SCN5A polymorphisms have altered electrophysiology when expressed in Q1077 splice variants. Heart Rhythm. 2005;2:741-747.
9. Tan BH, Valdivia CR, Song C, et al. Partial expression defect for the SCN5A missense mutation G1406R depends on splice variant background Q1077 and rescue by mexiletine. Am J Physiol Heart Circ Physiol. 2006;291:H1822-H1828.
10. Kaplan WD, Trout WE III. The behavior of four neurological mutants of Drosophila. Genetics. 1969;61:399-409.
11. Ganetzky B, Wu CF. Neurogenetic analysis of potassium currents in Drosophila: Synergistic effects on neuromuscular transmission in double mutants. J Neurogenet. 1983;1:17-28.
12. Ganetzky B, Wu CF. Neurogenetics of membrane excitability in Drosophila. Annu Rev Genet. 1986;20:13-44.
13. Guy HR, Durell SR, Warmke J, et al. Similarities in amino acid sequences of Drosophila eag and cyclic nucleotide-gated channels. Science. 1991; 254:730.
14. Bruggemann A, Pardo LA, Stuhmer W, et al. Ether-a-go-go encodes a voltage-gated channel permeable to K+ and Ca2+ and modulated by cAMP. Nature. 1993;365:445-448.
15. Sanguinetti MC, Jiang C, Curran ME, et al. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell. 1995;81:299-307.
16. Trudeau MC, Warmke JW, Ganetzky B, et al. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science. 1995; 269:92-95.
17. Shi W, Wymore RS, Wang HS, et al. Identification of two nervous system-specific members of the erg potassium channel gene family. J Neurosci. 1997;17:9423-9432.
18. Jones EM, Roti Roti EC, Wang J, et al. Cardiac IKr channels minimally comprise hERG 1a and 1b subunits. J Biol Chem. 2004;279: 44690-44694.
19. Torres AM, Bansal PS, Sunde M, et al. Structure of the HERG K+ channel S5P extracellular linker: role of an amphipathic alpha-helix in C-type inactivation. JBiol Chem. 2003;278:42136-42148.
20. Sanguinetti MC, Tristani-Firouzi M. HERG potassium channels and cardiac arrhythmia. Nature. 2006;440:463-469.
21. Tseng GN. I(Kr): the hERG channel. J Mol Cell Cardiol. 2001;33: 835-849.
22. Pardo-Lopez L, Zhang M, Liu J, et al. Mapping the binding site of a human ether-a-go-go-related gene-specific peptide toxin (ErgTx) to the channel's outer vestibule. JBiol Chem. 2002;277:16403-16411.
23. Rajamani S, Anderson CL, Valdivia CR, et al. Specific serine proteases selectively damage KCNH2 (hERG1) potassium channels and I(Kr). Am J Physiol Heart Circ Physiol. 2006;290:H1278-H1288.
24. Liu J, Zhang M, Jiang M, et al. Structural and functional role of the extracellular s5-p linker in the HERG potassium channel. J Gen Physiol. 2002;120:723-737.
25. Spector PS, Curran ME, Zou A, et al. Fast inactivation causes rectification of the IKr channel. J Gen Physiol. 1996;107:611-619.
26. Zhou Z, Gong Q, Ye B, et al. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys J. 1998;74:230-241.
27. Kapplinger JD, Tester DJ, Salisbury BA, et al. Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test. Heart Rhythm. 2009;6: 1297-1303
28. Sale H, Wang J, O'Hara TJ, et al. Physiological properties of hERG 1a/1b heteromeric currents and a hERG 1b-specific mutation associated with long-QT syndrome. Circ Res. 2008;103:e81-e95.
29. Zhou Z, Gong Q, Epstein ML, et al. HERG channel dysfunction in human long QT syndrome. Intracellular transport and functional defects. J Biol Chem. 1998;273:21061-21066.
30. Ficker E, Dennis AT, Wang L, et al. Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG. Circ Res. 2003;92:e87-e100.
31. Gong Q, Jones MA, Zhou Z. Mechanisms of pharmacological rescue of trafficking-defective hERG mutant channels in human long QT syndrome. JBiol Chem. 2006;281:4069-4074.
32. Gong Q, Keeney DR, Molinari M, et al. Degradation of trafficking- defective long QT syndrome type II mutant channels by the ubiquitin-proteasome pathway. JBiol Chem. 2005;280:19419-19425.
33. Walker VE, Atanasiu R, Lam H, et al. Co-chaperone FKBP38 promotes HERG trafficking. JBiol Chem. 2007;282:23509-23516.
34. Kupershmidt S, Yang T, Chanthaphaychith S, et al. Defective human ether-a-go-go-related gene trafficking linked to an endoplasmic reticulum retention signal in the C terminus. JBiol Chem. 2002;277:27442-27448.
35. Delisle BP, Underkofler HA, Moungey BM, et al. Small GTPase determinants for the golgi processing and plasmalemmal expression of human ether-a-go-go related (hERG) K+ channels. JBiol Chem. 2009;284:2844-2853.
36. Gu F, Crump CM, Thomas G. Trans-Golgi network sorting. Cell Mol Life Sci. 2001;58:1067-1084.
37. Gong Q, Anderson CL, January CT, et al. Role of glycosylation in cell surface expression and stability of HERG potassium channels. Am J Physiol Heart Circ Physiol. 2002;283:H77-H84.
38. Delisle BP, Anson BD, Rajamani S, et al. Biology of cardiac arrhythmias: ion channel protein trafficking. Circ Res. 2004;94:1418-1428.
39. Gong Q, Zhang L, Vincent GM, et al. Nonsense mutations in hERG cause a decrease in mutant mRNA transcripts by nonsense-mediated mRNA decay in human long-QT syndrome. Circulation. 2007;116:17-24.
40. Bhuiyan ZA, Momenah TS, Gong Q, et al. Recurrent intrauterine fetal loss due to near absence ofHERG: clinical and functional characterization of a homozygous nonsense HERG Q1070X mutation. Heart Rhythm. 2008;5:553-561.
41. Sanguinetti MC, Curran ME, Spector PS, et al. Spectrum of HERG K+-channel dysfunction in an inherited cardiac arrhythmia. Proc Natl Acad Sci USA. 1996;93:2208-2212.
42. Anderson CL, Delisle BP, Anson BD, et al. Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism. Circulation. 2006 113:365-373.
43. Delisle BP, Anderson CL, Balijepalli RC, et al. Thapsigargin selectively rescues the trafficking defective LQT2 channels G601S and F805C. JBiol Chem. 2003;278:35749-35754.
44. Cui J, Kagan A, Qin D, et al. Analysis of the cyclic nucleotide binding domain of the HERG potassium channel and interactions with KCNE2. JBiol Chem. 2001;276:17244-17251.
45. Paulussen A, Raes A, Matthijs G, et al. A novel mutation (T65P) in the PAS domain of the human potassium channel HERG results in the long QT syndrome by trafficking deficiency. J Biol Chem. 2002;277:48610-48616.
46. Amin AS, Herfst LJ, Delisle BP, et al. Fever-induced QTc prolongation and ventricular arrhythmias in individuals with type 2 congenital long QT syndrome. J Clin Invest. 2008;118:2552-2561.
47. Ficker E, Dennis AT, Obejero-Paz CA, et al. Retention in the endoplasmic reticulum as a mechanism of dominant-negative current suppression in human long QT syndrome. J Mol Cell Cardiol. 2000;32:2327-2337.
48. Zhou Z, Gong Q, January CT. Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome. Pharmacological and temperature effects. J Biol Chem. 1999;274:31123-31126.
49. Furutani M, Trudeau MC, Hagiwara N, et al. Novel mechanism associated with an inherited cardiac arrhythmia: defective protein trafficking by the mutant HERG (G601S) potassium channel. Circulation. 1999;99:2290-2294.
50. Huang FD, Chen J, Lin M, et al. Long-QT syndrome-associated missense mutations in the pore helix of the HERG potassium channel. Circulation. 2001;104:1071-1075.
51. Moss AJ, Zareba W, Kaufman ES, et al. Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation. 2002; 105:794-799.
52. Akhavan A, Atanasiu R, Shrier A. Identification of a COOH-terminal segment involved in maturation and stability of human ether-a-go-go-related gene potassium channels. J Biol Chem. 2003 278:40105-40112.
53. Anson BD, Ackerman MJ, Tester DJ, et al. Molecular and functional characterization of common polymorphisms in HERG (KCNH2) potassium channels. Am J Physiol Heart Circ Physiol. 2004;286:H2434-H2441.
54. Shimizu W, Moss AJ, Wilde AA, et al. Genotype-phenotype aspects of type-2 long-QT syndrome. J Am Coll Cardiol. 2009;54:2052-2062.
55. Kagan A, Yu Z, Fishman GI, et al. The dominant negative LQT2 mutation A561V reduces wild-type HERG expression. J Biol Chem. 2000;275: 11241-11248.
56. Ficker E, Thomas D, Viswanathan PC, et al. Novel characteristics of a misprocessed mutant HERG channel linked to hereditary long QT syndrome. Am J Physiol Heart Circ Physiol. 2000;279:H1748-H1756.
57. Gong Q, Anderson CL, January CT, et al. Pharmacological rescue of trafficking defective HERG channels formed by coassembly of wild-type and long QT mutant N470D subunits. Am J Physiol Heart Circ Physiol. 2004;287:H652-H658.
58. Denning GM, Anderson MP, Amara JF, et al. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature. 1992;358:761-764.
59. Loo TW, Clarke DM. Identification of residues in the drug-binding site of human P-glycoprotein using a thiol-reactive substrate. J Biol Chem. 1997; 272:31945-31948.
60. Yao Y, Teng S, Li N, et al. Aminoglycoside antibiotics restore functional expression oftruncated HERG channels produced by nonsense mutations. Heart Rhythm. 2009;6:553-560.
61. Grunnet M, Hansen RS, Olesen SP. hERG1 channel activators: a new antiarrhythmic principle. Prog Biophys Mol Biol. 2008;98:347-362.
62. Guo J, Massaeli H, Xu J, et al. Extracellular K+ concentration controls cell surface density of IKr in rabbit hearts and of the HERG channel in human cell lines. J Clin Invest. 2009;119:2745-2757.
63. Ficker E, Obejero-Paz CA, Zhao S, et al. The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-go-go-related gene (HERG) mutations. J Biol Chem. 2002;277:4989-4998.
64. Rajamani S, Anderson CL, Anson BD, et al. Pharmacological rescue of human K(+) channel long-QT2 mutations: human ether-a-go-go-related gene rescue without block. Circulation. 2002;105:2830-2835.
65. Van Goor F, Straley KS, Cao D, et al. Rescue of DF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol. 2006;290: L1117-L1130.
66. Kang J, Chen XL, Wang H, et al. Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel. Mol Pharmacol. 2005;67:827-836.
67. Hansen RS, Diness TG, Christ T, et al. Activation of human ether-a-go-go-related gene potassium channels by the diphenylurea 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643). Mol Pharmacol. 2006;69:266-277.
68. Hansen RS, Diness TG, Christ T, et al. Biophysical characterization of the new human ether-a-go-go-related gene channel opener NS3623 [N-(4-bromo-2-(1H-tetrazol-5-yl)-phenyl)-N'-(3′-trifluoromethylphenyl) urea]. Mol Pharmacol. 2006;70:1319-1329.
69. Zhou J, Augelli-Szafran CE, Bradley JA, et al. Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity. Mol Pharmacol. 2005;68: 876-884.
70. Zeng H, Lozinskaya IM, Lin Z, et al. Mallotoxin is a novel human ether-ago-go-related gene (hERG) potassium channel activator. JPharmacol Exp Ther. 2006;319:957-962.
71. Delisle BP, Slind JK, Kilby JA, et al. Intragenic suppression oftrafficking-defective KCNH2 channels associated with long QT syndrome. Mol Pharmacol. 2005;68:233-240.
72. Gustina AS, Trudeau MC. A recombinant N-terminal domain fully restores deactivation gating in N-truncated and long QT syndrome mutant hERG potassium channels. Proc Natl Acad Sci USA. 2009;106:13082-13087.
73. Perrin MJ, Subbiah RN, Vandenberg JI, et al. Human ether-a-go-go related gene (hERG) K+ channels: function and dysfunction. Prog Biophys Mol Biol. 2008;98:137-148.
74. Lees-Miller JP, Duan Y, Teng GQ, et al. Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. Mol Pharmacol. 2000;57:367-374.
75. Mitcheson JS, Chen J, Lin M, et al. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA. 2000;97:12329-12333.
76. van der Heyden MA, Smits ME, Vos MA. Drugs and trafficking of ion channels: a new pro-arrhythmic threat on the horizon? Br J Pharmacol. 2008;153:406-409.
77. Rajamani S, Eckhardt LL, Valdivia CR, et al. Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol. 2006;149:481-489.
78. Thomas D, Bloehs R, Koschny R, et al. Doxazosin induces apoptosis of cells expressing hERG K+ channels. Eur J Pharmacol. 2008;579:98-103.
79. Valdivia CR, Runwaldt KM, Makielski JC. Trafficking defective SCN5A Brugada syndrome mutations rescue by different class I antiarrhythmic drugs [abstract]. Heart Rhythm. 2005;2:S136.
80. Valdivia CR, Tester DJ, Rok BA, et al. A trafficking defective, Brugada syndrome-causing SCN5A mutation rescued by drugs. Cardiovasc Res. 2004;62:53-62.
81. Pfahnl AE, Viswanathan PC, Weiss R, et al. A sodium channel pore mutation causing Brugada syndrome. Heart Rhythm. 2007;4:46-53.
82. Poelzing S, Forleo C, Samodell M, et al. SCN5A polymorphism restores trafficking of a Brugada syndrome mutation on a separate gene. Circulation. 2006;114:368-376.
83. Yan FF, Casey J, Shyng SL. Sulfonylureas correct trafficking defects of disease-causing ATP-sensitive potassium channels by binding to the channel complex. JBiol Chem. 2006;281:33403-33413.
84. Wilson AJ, Quinn KV Graves FM, et al. Abnormal KCNQ1 trafficking influences disease pathogenesis in hereditary long QT syndromes (LQT1). Cardiovasc Res. 2005;67:476-486.
85. Ulloa-Aguirre A, Janovick JA, Brothers SP, et al. Pharmacologic rescue of conformationally-defective proteins: implications for the treatment of human disease. Traffic. 2004;5:821-837.
86. Bonuccelli G, Sotgia F, Capozza F, et al. Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation ofdystrophin and dystrophin-associated proteins in mdx mice. Cell Cycle. 2007;6:1242-1248.
87. Loo TW, Bartlett MC, Clarke DM. Rescue of DeltaF508 and other misprocessed CFTR mutants by a novel quinazoline compound. Mol Pharm. 2005;2:407-413.
88. Liu K, Yang T, Viswanathan PC, et al. New mechanism contributing to drug-induced arrhythmia: rescue of a misprocessed LQT3 mutant. Circulation. 2005;112:3239-3246.
89. Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007;447:87-91.
90. Rowe SM, Clancy JP. Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development. BioDrugs. 2009;23:165-174.
91. Mohler PJ, Rivolta I, Napolitano C, et al. Nav1.5 E1053K mutation causing Brugada syndrome blocks binding to ankyrin-G and expression of Nav1.5 on the surface of cardiomyocytes. Proc Natl Acad Sci USA. 2004; 101:17533-17538.
92. He JQ, January CT, Thomson JA, et al. Human embryonic stem cell-derived cardiomyocytes: drug discovery and safety pharmacology. Expert Opin Drug Discov. 2007;2:1-16.